文献速递前列腺癌

血清microRNA标志物预测前列腺癌主动监测中的重新分级

Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance.
PubMed 文献 · J Urol · 2017-12-12

研究纳入两个独立主动监测队列(训练组196例、验证组133例),均为Gleason评分6分且未治疗的前列腺癌患者,评估9种循环miRNA预测重新分级的能力。3-miR评分(miRNA-223、miRNA-24、miRNA-375)可显著预测重新分级(训练组OR 2.72,95%CI 1.50-4.94;验证组OR 3.70,95%CI 1.29-10.6),联合PSA时阴性预测值达89%-90%、特异性66%-81%。

要点

  • 3-miR评分可预测主动监测患者重新分级,训练组OR 2.72,验证组OR 3.70。
  • 3-miR评分在多变量模型中独立于临床特征。
  • 3-miR评分联合PSA的阴性预测值为89%-90%,特异性为66%-81%。

核心结论

  • 3-miR评分联合PSA是一种无创生物标志物组合,具有高阴性预测值,可能用于识别主动监测中真正惰性的前列腺癌患者。

研究设计与样本

  • 研究收集两个独立主动监测队列的血清样本,训练组196例、验证组133例,所有患者均为未治疗且诊断为Gleason评分6分的前列腺癌,样本在潜在重新分级前采集,分析9种既往与前列腺癌进展相关的循环miRNA。

主要发现

  • 3-miR评分(miRNA-223、miRNA-24、miRNA-375)显著预测患者重新分级,训练组OR 2.72(95%CI 1.50-4.94),验证组OR 3.70(95%CI 1.29-10.6)。
  • 3-miR评分在多变量模型中独立于临床特征。
  • ROC AUC在3-miR评分联合PSA时最大化,表明具有附加预测价值。
  • 3-miR评分联合PSA组合 cutoff 达到89%至90%的阴性预测值和66%至81%的特异性。

关键数值与推荐

  • 3-miR评分预测重新分级的训练组OR 2.72(95%CI 1.50-4.94),验证组OR 3.70(95%CI 1.29-10.6)。
  • 3-miR评分联合PSA的阴性预测值为89%至90%,特异性为66%至81%。

临床怎么用

  • 3-miR评分联合PSA可能用于识别主动监测中真正惰性的前列腺癌患者。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Conventional clinical variables cannot accurately differentiate indolent from aggressive prostate cancer in patients on active surveillance. We investigated promising circulating miRNA biomarkers to predict the reclassification of active surveillance cases. MATERIALS AND METHODS: We collected serum samples from 2 independent active surveillance cohorts of 196 and 133 patients for the training and validation, respectively, of candidate miRNAs. All patients were treatment naïve and diagnosed with Gleason score 6 prostate cancer. Samples were collected prior to potential reclassification. We analyzed 9 circulating miRNAs previously shown to be associated with prostate cancer progression. Logistic regression and ROC analyses were performed to assess the predictive ability of miRNAs and clinical variables. RESULTS: A 3-miR (miRNA-223, miRNA-24 and miRNA-375) score was significant to predict patient reclassification (training OR 2.72, 95% CI 1.50-4.94 and validation OR 3.70, 95% CI 1.29-10.6). It was independent of clinical characteristics in multivariable models. The ROC AUC was maximized when combining the 3-miR score and prostate specific antigen, indicating additive predictive value. The 3-miR score plus the prostate specific antigen panel cutoff achieved 89% to 90% negative predictive value and 66% to 81% specificity. CONCLUSIONS: The 3-miR score combined with prostate specific antigen represents a noninvasive biomarker panel with high negative predictive value. It may be used to identify patients on active surveillance who have truly indolent prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Liu RSC, Olkhov-Mitsel E, Jeyapala R, et al. Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance. J Urol. 2017. PMID: 29246734. doi:10.1016/j.juro.2017.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。